Sep. 30 at 3:49 PM
Nanobiotix shares rose Tuesday after positive clinical trial data for its cancer treatment JNJ-1900 (NBTXR3) were presented at the American Society for Radiation Oncology annual meeting. The Phase 1 trial in recurrent/metastatic head and neck squamous cell carcinoma showed a 37% objective response in PD-1–naive patients and 32% in PD-1–resistant patients, exceeding typical 13–18% responses with checkpoint inhibitor monotherapy. Median overall survival reached 15.5 months in PD-1–naive and 11.4 months in PD-1–resistant patients. The therapy was well tolerated in 103 heavily pretreated patients, with only five experiencing grade ≥3 treatment-related adverse events. Disease control was seen in 95% of injected lesions, supporting further randomized trials.
$NBTX